Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Panacea CANINE is a hemp-derived veterinary supplement developed by Panacea Life Sciences, specifically formulated for dogs. Marketed under the brand name PANA Pet, it contains THC-free cannabidiol (CBD) as its primary active ingredient, often combined with fish oil in softgel or tincture formats. The product is intended to address a variety of canine health concerns, including chronic pain, arthritis, anxiety, cancer-related symptoms, and post-surgical recovery. As a cannabinoid-based natural product, it interacts with the endocannabinoid system to provide anti-inflammatory and analgesic effects, though it is classified as a nutraceutical rather than an FDA-approved pharmaceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Panacea CANINE.